Esther H Lips

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. doi request reprint Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
    Esther H Lips
    Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 136:35-43. 2012
  2. pmc Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
    Esther H Lips
    Department of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Breast Cancer Res 13:R107. 2011
  3. doi request reprint Platform comparisons for identification of breast cancers with a BRCA-like copy number profile
    Philip C Schouten
    Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands
    Breast Cancer Res Treat 139:317-27. 2013
  4. ncbi request reprint Combined use of (18)F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy
    Kenneth E Pengel
    Department of Radiology, The Netherlands Cancer Institute, PO Box 90203, 1006 BE, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 41:1515-24. 2014
  5. doi request reprint SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer
    Jorma J de Ronde
    Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 137:213-23. 2013
  6. pmc Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes
    Jorma J de Ronde
    Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    PLoS ONE 9:e88551. 2014

Collaborators

Detail Information

Publications6

  1. doi request reprint Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
    Esther H Lips
    Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 136:35-43. 2012
    ..However, this difference is explained by differences in molecular characteristics, particularly HR and HER2, and independent of lobular histology...
  2. pmc Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
    Esther H Lips
    Department of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Breast Cancer Res 13:R107. 2011
    ....
  3. doi request reprint Platform comparisons for identification of breast cancers with a BRCA-like copy number profile
    Philip C Schouten
    Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands
    Breast Cancer Res Treat 139:317-27. 2013
    ..Our findings suggest that it is possible to map copy number data from any other technology in a similar way...
  4. ncbi request reprint Combined use of (18)F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy
    Kenneth E Pengel
    Department of Radiology, The Netherlands Cancer Institute, PO Box 90203, 1006 BE, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 41:1515-24. 2014
    ..To explore the potential complementary value of PET/CT and dynamic contrast-enhanced MRI in predicting pathological response to neoadjuvant chemotherapy (NAC) of breast cancer and the dependency on breast cancer subtype...
  5. doi request reprint SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer
    Jorma J de Ronde
    Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 137:213-23. 2013
    ....
  6. pmc Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes
    Jorma J de Ronde
    Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    PLoS ONE 9:e88551. 2014
    ....